News

CooperVision Presents Expansive Scientific Research During 2021 BCLA Virtual Conference

Company’s Commitment to Evidence-Based Development Demonstrated by More than 20 Papers and Posters Delivered to Global Attendees

Read More

New Look Vision Group Regains Its Freedom

In the May-June issue of Optik Magazine, contributor Jean-François Venne had a chat with Antoine Amiel from New Look Vision.

Read More

MIDO Sets February 2022 Date for In-Person Edition

The Digital Edition has closed but B2B trading on the platform continues. The three days on line yielded impressive numbers, with almost 50,000 interactions on the business platform, 438 display pages and over 5,700 registered users.

Read More

Essilor, New Official Partner of 24 Hours of Le Mans and MissionH24

With the next 24 Hours of Le Mans fast approaching (21-22 August), race organizer the Automobile Club de l’Ouest (ACO) announces a three-year partnership with Essilor.

Read More

Cholesterol Lowering Statin Drug May Promote Retinal Neuron Regeneration

FBC funded researcher Dr. Philippe Monnier has published a study in the journal Neurobiology of Disease that shows that cholesterol inhibition increases neuron regeneration and survival.

Read More

Eyes on Sheppard Honoured with MIDO Award

Eyes on Sheppard wins first-ever MIDO award

Read More

EUFLUORIA: Euphoria Capsule Collection

Etnia Barcelona presents their new capsule collection bursting with contrast and inspired by a range of fluorescent colours.

Read More

Men’s Eyewear for the Discerning Gent!

May-June issue of Optik Magazine features IMAGINEM, which highlights advice from Eye Styling Expert Wendy Buchanan, R.O. on everything MEN!

Read More

Essilor Supports IMI’s 2021 Series of White Papers on Myopia

The International Myopia Institute (IMI) recently released the 2021 edition of white papers in a special issue of the peer-reviewed Investigative Ophthalmology and Visual Science (IOVS) journal.

Read More

Bausch + Lomb and Clearside Biomedical Announce U.S. FDA Filing Acceptance for XIPERE

Bausch + Lomb, along with Clearside Biomedical announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted New Drug Application for XIPERE™.

Read More